
Nicolas Pietrancosta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7149947/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Imino-tetrahydro-benzothiazole Derivatives as p53 Inhibitors:Â Discovery of a Highly Potent in Vivo Inhibitor and Its Action Mechanism. Journal of Medicinal Chemistry, 2006, 49, 3645-3652.	6.4	100
2	Naphthyl and Coumarinyl Biarylpiperazine Derivatives as Highly Potent Human β-Secretase Inhibitors. Design, Synthesis, and Enzymatic BACE-1 and Cell Assays. Journal of Medicinal Chemistry, 2006, 49, 4275-4285.	6.4	60
3	New 2-bromomethyl-8-substituted-benzo[c]chromen-6-ones. Synthesis and biological properties. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 135-138.	2.2	59
4	Synthesis of Quinoline Dicarboxylic Esters as Biocompatible Fluorescent Tags. Journal of Organic Chemistry, 2012, 77, 8294-8302.	3.2	55
5	BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: Chromene, coumarin and quinoline. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1995-1999.	2.2	50
6	Novel cyclized Pifithrin-α p53 inactivators: synthesis and biological studies. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1561-1564.	2.2	36
7	Clinical or ATPase domain mutations in ABCD4 disrupt the interaction between the vitamin B12-trafficking proteins ABCD4 and LMBD1. Journal of Biological Chemistry, 2017, 292, 11980-11991.	3.4	36
8	Structure of the essential peptidoglycan amidotransferase MurT/GatD complex from Streptococcus pneumoniae. Nature Communications, 2018, 9, 3180.	12.8	34
9	5′-Methylene-triazole-substituted-aminoribosyl uridines as MraY inhibitors: synthesis, biological evaluation and molecular modeling. Organic and Biomolecular Chemistry, 2015, 13, 7193-7222.	2.8	33
10	Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement. Nature Communications, 2017, 8, 14253.	12.8	33
11	Molecular, Structural, Functional, and Pharmacological Sites for Vesicular Glutamate Transporter Regulation. Molecular Neurobiology, 2020, 57, 3118-3142.	4.0	31
12	1,1′-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: A new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3298-3301.	2.2	29
13	Rose Bengal analogs and vesicular glutamate transporters (VGLUTs). Bioorganic and Medicinal Chemistry, 2010, 18, 6922-6933.	3.0	26
14	Purification and characterization of recombinant human liver glycolate oxidase. Archives of Biochemistry and Biophysics, 2007, 465, 410-416.	3.0	25
15	Pseudomonas aeruginosa Lipoxygenase LoxA Contributes to Lung Infection by Altering the Host Immune Lipid Signaling. Frontiers in Microbiology, 2019, 10, 1826.	3.5	25
16	Simple Coupling Reaction between Amino Acids and Weakly Nucleophilic Heteroaromatic Amines. ACS Combinatorial Science, 2004, 6, 695-698.	3.3	24
17	Enhanced delivery of γ-secretase inhibitor DAPT into the brain via an ascorbic acid mediated strategy. Organic and Biomolecular Chemistry, 2005, 3, 2450.	2.8	24
18	Structure of human glycolate oxidase in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1,2,3-thiadiazole. Acta Crystallographica Section F: Structural Biology Communications, 2009, 65, 1246-1253.	0.7	24

NICOLAS PIETRANCOSTA

#	Article	IF	CITATIONS
19	Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression. Molecular Psychiatry, 2020, 25, 1245-1259.	7.9	24
20	Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors. European Journal of Medicinal Chemistry, 2014, 78, 236-247.	5.5	22
21	Substituted thiazolamide coupled to a redox delivery system: a new Î ³ -secretase inhibitor with enhanced pharmacokinetic profile. Organic and Biomolecular Chemistry, 2005, 3, 612-618.	2.8	19
22	CYP2U1 activity is altered by missense mutations in hereditary spastic paraplegia 56. Human Mutation, 2018, 39, 140-151.	2.5	19
23	A new Met inhibitory-scaffold identified by a focused forward chemical biological screen. Biochemical and Biophysical Research Communications, 2008, 375, 184-189.	2.1	16
24	Expression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 1426-1437.	2.4	16
25	Characterization of a Human Point Mutation of VGLUT3 (p.A211V) in the Rodent Brain Suggests a Nonuniform Distribution of the Transporter in Synaptic Vesicles. Journal of Neuroscience, 2017, 37, 4181-4199.	3.6	15
26	Prospects for the Resistance to HIV Protease Inhibitors: Current Drug Design Approaches and Perspectives. Current Pharmaceutical Design, 2005, 11, 3077-3090.	1.9	14
27	Synthesis and anti-HIV properties of new hydroxyquinoline–polyamine conjugates on cells infected by HIV-1 LAV and HIV-1 BaL viral strains. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5988-5992.	2.2	11
28	Successful Prediction of Substrate-binding Pocket in SLC17 Transporter Sialin. Journal of Biological Chemistry, 2012, 287, 11489-11497.	3.4	11
29	Ctr9, a Protein in the Transcription Complex Paf1, Regulates Dopamine Transporter Activity at the Plasma Membrane. Journal of Biological Chemistry, 2015, 290, 17848-17862.	3.4	11
30	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin. Journal of Medicinal Chemistry, 2020, 63, 8231-8249.	6.4	11
31	Bacterial Transferase MraY, a Source of Inspiration towards New Antibiotics. Current Medicinal Chemistry, 2019, 25, 6013-6029.	2.4	11
32	Identification of Primary Natural Killer Cell Modulators by Chemical Library Screening with a Luciferase-Based Functional Assay. SLAS Discovery, 2019, 24, 25-37.	2.7	10
33	Spectral and 3D model studies of the interaction of orphan human cytochrome P450 2U1 with substrates and ligands. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 3144-3153.	2.4	9
34	Regulation of IRE1 RNase activity by the Ribonuclease inhibitor 1 (RNH1). Cell Cycle, 2018, 17, 1901-1916.	2.6	9
35	Synthesis of New Substituted 4,5-Dihydro-3H-spiro[1,5]-benzoxazepine-2,4′-piperidine and Biological Properties. Australian Journal of Chemistry, 2006, 59, 812.	0.9	8
36	Thiazolamide - Ascorbic Acid Conjugate: a Î ³ -Secretase Inhibitor with Enhanced Blood - Brain Barrier Permeation. Australian Journal of Chemistry, 2007, 60, 128.	0.9	8

#	Article	IF	CITATIONS
37	Synthesis and biological activity of <i>N</i> -substituted spiro[benzoxazepine-piperidine] Aβ-peptide production inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2008, 23, 996-1001.	5.2	8
38	Membrane-bound human orphan cytochrome P450 2U1: Sequence singularities, construction of a full 3D model, and substrate docking. Biochimie, 2017, 140, 166-175.	2.6	7
39	Structural and Functional Characterization of the Interaction of Snapin with the Dopamine Transporter: Differential Modulation of Psychostimulant Actions. Neuropsychopharmacology, 2018, 43, 1041-1051.	5.4	7
40	Destabilization of the human RED–SMU1 splicing complex as a basis for host-directed antiinfluenza strategy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10968-10977.	7.1	7
41	LSP5-2157 a new inhibitor of vesicular glutamate transporters. Neuropharmacology, 2020, 164, 107902.	4.1	7
42	Design of β-Secretase Inhibitors by Introduction of a Mandelyl Moiety in DAPT Analogues. Australian Journal of Chemistry, 2005, 58, 585.	0.9	6
43	Leveraging VGLUT3 Functions to Untangle Brain Dysfunctions. Trends in Pharmacological Sciences, 2021, 42, 475-490.	8.7	4
44	Identification of Privileged Scaffolds from a Diversified Chemical Library forβ-Secretase Inhibition. Letters in Drug Design and Discovery, 2005, 2, 595-600.	0.7	3
45	Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope. Journal of Immunology Research, 2019, 2019, 1-13.	2.2	3
46	Are p53 inhibitors potentially useful therapeutics?. Drug Development Research, 2005, 65, 43-49.	2.9	2
47	The Orphan GPCR Receptor, GPR88, Interacts with Nuclear Protein Partners in the Cerebral Cortex. Cerebral Cortex, 2022, 32, 479-489.	2.9	1
48	CADPS functional mutations in patients with bipolar disorder increase the sensitivity to stress. Molecular Psychiatry, 2022, 27, 1145-1157.	7.9	1
49	New 2-Bromomethyl-8-substituted-benzo[c]chromen-6-ones. Synthesis and Biological Properties ChemInform, 2005, 36, no.	0.0	0
50	Novel Cyclized Pifithrin-α p53 Inactivators: Synthesis and Biological Studies ChemInform, 2005, 36, no.	0.0	0
51	Chemical pollution and innate antiviral immunity: Dangerous Liaisons ?. Virologie, 2018, 22, 1-13.	0.1	0